<DOC>
	<DOCNO>NCT02280629</DOCNO>
	<brief_summary>The purpose study prove superiority 48-weeks treatment 3.2 g/day delayed-release phosphatidylcholine ( LT-02 ) versus placebo maintenance remission patient ulcerative colitis ( UC )</brief_summary>
	<brief_title>Phosphatidylcholine ( LT-02 ) v . Placebo vs. Mesalamine Maintenance Remission Ulcerative Colitis ( PROTECT-2 )</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Major Signed inform consent Men woman , 18 70 year age Historically confirm diagnosis UC endoscopy histology Patients clinical endoscopical remission baseline Negative pregnancy test female childbearing potential baseline visit Major Crohn 's disease , indeterminate colitis , ischemic colitis , radiation colitis , microscopic colitis ( i.e. , collagenous colitis lymphocytic colitis ) , diverticular disease associate colitis Toxic megacolon fulminant colitis Colon resection Malabsorption syndromes Celiac disease Bleeding hemorrhoids Other inflammatory bleed disorder colon intestine , disease may cause diarrhea gastrointestinal bleeding History presence ischemic heart disease , myocardial infarction , peripheral arterial disease , ischemic stroke , transient ischemic attack Any severe concomitant renal , endocrine , psychiatric disorder , opinion investigator might influence patient 's compliance interpretation result Any relevant know systemic disease ( e.g. , AIDS , active tuberculosis ) Severe comorbidity substantially reduce life expectancy History cancer last five year Abnormal hepatic function screen visit , liver cirrhosis Abnormal renal function screen visit Patients know hypersensitivity soy Known intolerance/hypersensitivity Investigational Medicinal Product ( IMP : LT02 mesalamine ) Treatment steroid ( oral , inhalative , intravenous [ IV ] ) , cyclosporine tacrolimus within last 4 week prior randomization Treatment methotrexate within last 6 week prior randomization Treatment TNFalphaantagonists , azathioprine , 6mercaptopurine , antiintegrin therapy within last 8 week prior randomization Treatment rectal mesalamine corticosteroid formulation within last 2 week prior randomization Treatment investigational drug within last 12 week prior randomization except LT02 Existing intend pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>